CN103609944A - 降血压助眠的保健食品 - Google Patents
降血压助眠的保健食品 Download PDFInfo
- Publication number
- CN103609944A CN103609944A CN201310664187.0A CN201310664187A CN103609944A CN 103609944 A CN103609944 A CN 103609944A CN 201310664187 A CN201310664187 A CN 201310664187A CN 103609944 A CN103609944 A CN 103609944A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- hypotensive
- sleeping
- health food
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000036772 blood pressure Effects 0.000 title abstract description 21
- 235000013305 food Nutrition 0.000 title abstract description 15
- 230000001737 promoting effect Effects 0.000 title abstract description 4
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims abstract description 34
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229940026510 theanine Drugs 0.000 claims abstract description 17
- 229940088594 vitamin Drugs 0.000 claims abstract description 15
- 229930003231 vitamin Natural products 0.000 claims abstract description 15
- 235000013343 vitamin Nutrition 0.000 claims abstract description 15
- 239000011782 vitamin Substances 0.000 claims abstract description 15
- 229960003080 taurine Drugs 0.000 claims abstract description 12
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 6
- 235000010755 mineral Nutrition 0.000 claims abstract description 6
- 239000011707 mineral Substances 0.000 claims abstract description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 24
- 230000001077 hypotensive effect Effects 0.000 claims description 23
- 229960003495 thiamine Drugs 0.000 claims description 23
- 208000001953 Hypotension Diseases 0.000 claims description 22
- 208000021822 hypotensive Diseases 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 18
- 235000013402 health food Nutrition 0.000 claims description 17
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 16
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 16
- 239000011575 calcium Substances 0.000 claims description 16
- 229910052791 calcium Inorganic materials 0.000 claims description 16
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 16
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 13
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 12
- 229930003268 Vitamin C Natural products 0.000 claims description 12
- 235000019154 vitamin C Nutrition 0.000 claims description 12
- 239000011718 vitamin C Substances 0.000 claims description 12
- 229920002472 Starch Polymers 0.000 claims description 11
- 239000011734 sodium Substances 0.000 claims description 11
- 229910052708 sodium Inorganic materials 0.000 claims description 11
- 235000015424 sodium Nutrition 0.000 claims description 11
- 235000019698 starch Nutrition 0.000 claims description 11
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 10
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 10
- 229930003451 Vitamin B1 Natural products 0.000 claims description 10
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 10
- 239000011691 vitamin B1 Substances 0.000 claims description 10
- 235000010374 vitamin B1 Nutrition 0.000 claims description 10
- 239000008107 starch Substances 0.000 claims description 9
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 8
- 229930003427 Vitamin E Natural products 0.000 claims description 8
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 8
- 239000011781 sodium selenite Substances 0.000 claims description 8
- 235000015921 sodium selenite Nutrition 0.000 claims description 8
- 229960001471 sodium selenite Drugs 0.000 claims description 8
- 235000019158 vitamin B6 Nutrition 0.000 claims description 8
- 239000011726 vitamin B6 Substances 0.000 claims description 8
- 235000019165 vitamin E Nutrition 0.000 claims description 8
- 239000011709 vitamin E Substances 0.000 claims description 8
- 229940046009 vitamin E Drugs 0.000 claims description 8
- 229940011671 vitamin b6 Drugs 0.000 claims description 8
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 7
- 239000011777 magnesium Substances 0.000 claims description 7
- 229910052749 magnesium Inorganic materials 0.000 claims description 7
- 229910052711 selenium Inorganic materials 0.000 claims description 7
- 239000011669 selenium Substances 0.000 claims description 7
- 229940091258 selenium supplement Drugs 0.000 claims description 7
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 6
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 5
- 235000010216 calcium carbonate Nutrition 0.000 claims description 5
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 5
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 5
- 239000000395 magnesium oxide Substances 0.000 claims description 5
- 235000012245 magnesium oxide Nutrition 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims description 5
- 235000006076 zinc citrate Nutrition 0.000 claims description 5
- 102000040350 B family Human genes 0.000 claims description 4
- 108091072128 B family Proteins 0.000 claims description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000011746 zinc citrate Substances 0.000 claims description 4
- 229940068475 zinc citrate Drugs 0.000 claims description 4
- 150000003752 zinc compounds Chemical class 0.000 claims description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 4
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 102000008114 Selenoproteins Human genes 0.000 claims description 2
- 108010074686 Selenoproteins Proteins 0.000 claims description 2
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 claims description 2
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 2
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 claims description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 2
- 239000001354 calcium citrate Substances 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 239000011655 sodium selenate Substances 0.000 claims description 2
- 235000018716 sodium selenate Nutrition 0.000 claims description 2
- 229960001881 sodium selenate Drugs 0.000 claims description 2
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 2
- 239000011667 zinc carbonate Substances 0.000 claims description 2
- 235000004416 zinc carbonate Nutrition 0.000 claims description 2
- 229910000010 zinc carbonate Inorganic materials 0.000 claims description 2
- 239000011592 zinc chloride Substances 0.000 claims description 2
- 235000005074 zinc chloride Nutrition 0.000 claims description 2
- 239000011670 zinc gluconate Substances 0.000 claims description 2
- 235000011478 zinc gluconate Nutrition 0.000 claims description 2
- 229960000306 zinc gluconate Drugs 0.000 claims description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 2
- 239000011686 zinc sulphate Substances 0.000 claims description 2
- 235000009529 zinc sulphate Nutrition 0.000 claims description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract description 26
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract description 25
- 230000002040 relaxant effect Effects 0.000 abstract description 5
- 229920001542 oligosaccharide Polymers 0.000 abstract description 2
- 150000002482 oligosaccharides Chemical class 0.000 abstract description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 abstract 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 abstract 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 abstract 1
- 235000015097 nutrients Nutrition 0.000 abstract 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 239000011721 thiamine Substances 0.000 description 13
- 210000004556 brain Anatomy 0.000 description 12
- 230000006870 function Effects 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 7
- 206010022437 insomnia Diseases 0.000 description 7
- 208000002173 dizziness Diseases 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
- ASARMUCNOOHMLO-WLORSUFZSA-L cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ASARMUCNOOHMLO-WLORSUFZSA-L 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 208000034189 Sclerosis Diseases 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000003143 atherosclerotic effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000002464 muscle smooth vascular Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 230000003860 sleep quality Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 2
- 208000034710 Cerebral arteriovenous malformation Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000002263 Intracranial Arteriovenous Malformations Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241001122767 Theaceae Species 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 201000000034 arteriovenous malformations of the brain Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000008344 brain blood flow Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229960003563 calcium carbonate Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000003371 gabaergic effect Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- WAGPFYGOLZGETK-UHFFFAOYSA-N 1-(1h-indol-2-yl)propan-2-one Chemical compound C1=CC=C2NC(CC(=O)C)=CC2=C1 WAGPFYGOLZGETK-UHFFFAOYSA-N 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000050051 Chelone glabra Species 0.000 description 1
- 102000010792 Chromogranin A Human genes 0.000 description 1
- 108010038447 Chromogranin A Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 241000186685 Lactobacillus hilgardii Species 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000015345 genetic hypertension Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000011616 hypertension animal model Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000011224 negative regulation of urine volume Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001869 rapid Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 108010050939 thrombocytin Proteins 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310664187.0A CN103609944B (zh) | 2013-12-10 | 2013-12-10 | 降血压助眠的保健食品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310664187.0A CN103609944B (zh) | 2013-12-10 | 2013-12-10 | 降血压助眠的保健食品 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103609944A true CN103609944A (zh) | 2014-03-05 |
CN103609944B CN103609944B (zh) | 2015-05-13 |
Family
ID=50160679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310664187.0A Active CN103609944B (zh) | 2013-12-10 | 2013-12-10 | 降血压助眠的保健食品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103609944B (zh) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104305229A (zh) * | 2014-11-05 | 2015-01-28 | 广西壮族自治区农业科学院农产品加工研究所 | 一种石斛膳食纤维食品及其加工方法 |
CN104366510A (zh) * | 2014-11-28 | 2015-02-25 | 北京康比特体育科技股份有限公司 | 茶叶茶氨酸保健食品组合物及其制备方法 |
CN104489703A (zh) * | 2015-01-09 | 2015-04-08 | 青岛泉佳美硅藻泥科技有限公司 | 一种硅藻保健粉及其制备方法 |
CN104783289A (zh) * | 2015-03-25 | 2015-07-22 | 孙伟 | γ-氨基丁酸五联益生菌固体饮料的配方及制备方法 |
CN105341947A (zh) * | 2015-10-27 | 2016-02-24 | 江西美庐乳业集团有限公司 | 一种改善睡眠的营养包 |
CN105942533A (zh) * | 2016-06-29 | 2016-09-21 | 成都博创必成医药技术有限公司 | 一种功能性饮料及功能性饮料泡腾片 |
CN106923115A (zh) * | 2015-12-30 | 2017-07-07 | 上海医药集团股份有限公司 | 含西红花的植物饮料及其制备方法和应用 |
CN107136506A (zh) * | 2017-05-16 | 2017-09-08 | 陕西思尔生物科技有限公司 | 一种具有降血压功效的黑果腺肋花楸片及其制备方法 |
JP2018012681A (ja) * | 2016-07-07 | 2018-01-25 | 株式会社東洋新薬 | 経口組成物 |
CN107927732A (zh) * | 2017-12-15 | 2018-04-20 | 浙江中医药大学 | 一种预防抑郁及老年痴呆的保健食品及其制备方法 |
CN108094646A (zh) * | 2017-12-19 | 2018-06-01 | 北京特食生物科技研究中心(有限合伙) | 一种缓解压力的功能糖果及其制备方法 |
CN110050929A (zh) * | 2018-01-19 | 2019-07-26 | 辽宁科硕营养科技股份有限公司 | 一种具有补钙、改善睡眠和抗焦虑作用的功能饮料 |
CN110898081A (zh) * | 2019-10-29 | 2020-03-24 | 广东医科大学 | 具有助眠美肤作用的外用按摩制剂 |
CN111248370A (zh) * | 2020-02-17 | 2020-06-09 | 肖海东 | 一种具有调理睡眠障碍功能的液体饮料 |
CN111466444A (zh) * | 2020-04-16 | 2020-07-31 | 广州麦乐生物科技有限公司 | 一种促进儿童身高发育的配方奶粉及其制备方法 |
CN113181366A (zh) * | 2021-05-12 | 2021-07-30 | 杭州诺莘科技有限责任公司 | 含gaba和cb1受体激动剂的营养组合物及其制备和应用 |
CN113973965A (zh) * | 2021-10-29 | 2022-01-28 | 上海圣岳生物科技有限公司 | 含茶氨酸复合物使人心情放松的压片糖果及其制备方法 |
CN114097912A (zh) * | 2022-01-28 | 2022-03-01 | 北京岳达生物科技有限公司 | 一种速溶助眠茶及其制备方法 |
CN115066186A (zh) * | 2020-02-07 | 2022-09-16 | 雀巢产品有限公司 | 睡眠膳食补充剂 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1561768A (zh) * | 2004-04-09 | 2005-01-12 | 李卫平 | 改善睡眠的功能性晚安奶 |
CN102302480A (zh) * | 2011-07-13 | 2012-01-04 | 李晓莉 | 牛磺酸在抗睡眠剥夺应激损伤中的应用 |
CN102415523A (zh) * | 2010-09-26 | 2012-04-18 | 保龄宝生物股份有限公司 | 含有复合功能食品因子的组合物 |
CN103141855A (zh) * | 2013-03-04 | 2013-06-12 | 潍坊易思特生物科技有限公司 | 一种能够改善睡眠质量的保健品及其制备方法 |
-
2013
- 2013-12-10 CN CN201310664187.0A patent/CN103609944B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1561768A (zh) * | 2004-04-09 | 2005-01-12 | 李卫平 | 改善睡眠的功能性晚安奶 |
CN102415523A (zh) * | 2010-09-26 | 2012-04-18 | 保龄宝生物股份有限公司 | 含有复合功能食品因子的组合物 |
CN102302480A (zh) * | 2011-07-13 | 2012-01-04 | 李晓莉 | 牛磺酸在抗睡眠剥夺应激损伤中的应用 |
CN103141855A (zh) * | 2013-03-04 | 2013-06-12 | 潍坊易思特生物科技有限公司 | 一种能够改善睡眠质量的保健品及其制备方法 |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104305229A (zh) * | 2014-11-05 | 2015-01-28 | 广西壮族自治区农业科学院农产品加工研究所 | 一种石斛膳食纤维食品及其加工方法 |
CN104366510A (zh) * | 2014-11-28 | 2015-02-25 | 北京康比特体育科技股份有限公司 | 茶叶茶氨酸保健食品组合物及其制备方法 |
CN104366510B (zh) * | 2014-11-28 | 2016-06-29 | 北京康比特体育科技股份有限公司 | 茶叶茶氨酸保健食品组合物及其制备方法 |
CN104489703A (zh) * | 2015-01-09 | 2015-04-08 | 青岛泉佳美硅藻泥科技有限公司 | 一种硅藻保健粉及其制备方法 |
CN104783289A (zh) * | 2015-03-25 | 2015-07-22 | 孙伟 | γ-氨基丁酸五联益生菌固体饮料的配方及制备方法 |
CN105341947A (zh) * | 2015-10-27 | 2016-02-24 | 江西美庐乳业集团有限公司 | 一种改善睡眠的营养包 |
CN105341947B (zh) * | 2015-10-27 | 2017-05-17 | 江西美庐乳业集团有限公司 | 一种改善睡眠的营养包 |
CN106923115A (zh) * | 2015-12-30 | 2017-07-07 | 上海医药集团股份有限公司 | 含西红花的植物饮料及其制备方法和应用 |
CN105942533A (zh) * | 2016-06-29 | 2016-09-21 | 成都博创必成医药技术有限公司 | 一种功能性饮料及功能性饮料泡腾片 |
CN105942533B (zh) * | 2016-06-29 | 2019-06-11 | 成都博创必成医药技术有限公司 | 一种功能性饮料及功能性饮料泡腾片 |
JP2018012681A (ja) * | 2016-07-07 | 2018-01-25 | 株式会社東洋新薬 | 経口組成物 |
JP7037161B2 (ja) | 2016-07-07 | 2022-03-16 | 株式会社東洋新薬 | 経口組成物 |
CN107136506A (zh) * | 2017-05-16 | 2017-09-08 | 陕西思尔生物科技有限公司 | 一种具有降血压功效的黑果腺肋花楸片及其制备方法 |
CN107927732A (zh) * | 2017-12-15 | 2018-04-20 | 浙江中医药大学 | 一种预防抑郁及老年痴呆的保健食品及其制备方法 |
CN108094646A (zh) * | 2017-12-19 | 2018-06-01 | 北京特食生物科技研究中心(有限合伙) | 一种缓解压力的功能糖果及其制备方法 |
CN110050929A (zh) * | 2018-01-19 | 2019-07-26 | 辽宁科硕营养科技股份有限公司 | 一种具有补钙、改善睡眠和抗焦虑作用的功能饮料 |
CN110898081A (zh) * | 2019-10-29 | 2020-03-24 | 广东医科大学 | 具有助眠美肤作用的外用按摩制剂 |
CN115066186A (zh) * | 2020-02-07 | 2022-09-16 | 雀巢产品有限公司 | 睡眠膳食补充剂 |
CN111248370A (zh) * | 2020-02-17 | 2020-06-09 | 肖海东 | 一种具有调理睡眠障碍功能的液体饮料 |
CN111466444A (zh) * | 2020-04-16 | 2020-07-31 | 广州麦乐生物科技有限公司 | 一种促进儿童身高发育的配方奶粉及其制备方法 |
CN113181366A (zh) * | 2021-05-12 | 2021-07-30 | 杭州诺莘科技有限责任公司 | 含gaba和cb1受体激动剂的营养组合物及其制备和应用 |
CN113973965A (zh) * | 2021-10-29 | 2022-01-28 | 上海圣岳生物科技有限公司 | 含茶氨酸复合物使人心情放松的压片糖果及其制备方法 |
CN113973965B (zh) * | 2021-10-29 | 2023-10-13 | 上海圣岳生物科技有限公司 | 含茶氨酸复合物使人心情放松的压片糖果及其制备方法 |
CN114097912A (zh) * | 2022-01-28 | 2022-03-01 | 北京岳达生物科技有限公司 | 一种速溶助眠茶及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103609944B (zh) | 2015-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103609944B (zh) | 降血压助眠的保健食品 | |
CN107927732A (zh) | 一种预防抑郁及老年痴呆的保健食品及其制备方法 | |
CN101156685A (zh) | 营养保健粥 | |
CN105166295A (zh) | 一种富含伽马氨基丁酸和蛹虫草压片糖果及其制备方法 | |
CN109511742A (zh) | 一种助眠植物蛋白发酵饮料及其制备方法 | |
CN109820905A (zh) | 一种治疗失眠的药物组合物及其应用 | |
CN1780562B (zh) | 含甘氨酸食品及其应用 | |
CN102090563A (zh) | 一种纾压和舒眠的保健食品及其制备方法 | |
CN101637265A (zh) | 一种用于改善睡眠的保健食品 | |
CN103461585B (zh) | 补气养生中药茶 | |
CN101669624A (zh) | 一种具有改善妇女贫血功能的中药八宝茶及其制备方法 | |
CN102106577B (zh) | 天然有机可提高男性睡眠质量的饮料 | |
AU2016277326B2 (en) | Composition for weight reduction comprising a beverage and beads | |
CN103747791B (zh) | 蜂蜜与l‑丙氨酰‑l‑谷氨酰胺的组合物 | |
CN101955874B (zh) | 一种苦杏酒的酿造方法 | |
CN104957561A (zh) | 一种具有改善睡眠帮助缓解压力的组合物及其制剂 | |
CN109770169A (zh) | 一种有助于睡眠的粥 | |
CN104225228B (zh) | 一种用于调节血糖的中药制剂 | |
CN102925594A (zh) | 高甜蔗糖、高甜零度蔗糖及它们的制备方法 | |
CN110973326A (zh) | 一种能够改善人体亚健康的压片糖果及其制备方法 | |
CN103141855B (zh) | 一种能够改善睡眠质量的保健品及其制备方法 | |
CN105831735A (zh) | 藜麦婴幼儿超级营养粉 | |
CN111493314A (zh) | 一种具有生物活性物质的食材营养素及固体饮品 | |
CN106616955A (zh) | 一种改善睡眠的保健品的制作方法 | |
CN111838671A (zh) | 一种改善睡眠作用的强化营养素谷物膳食及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Health food that lowers blood pressure and helps sleep Effective date of registration: 20220831 Granted publication date: 20150513 Pledgee: Industrial Bank Co.,Ltd. Shanghai Putuo sub branch Pledgor: NANTONG LICHENG BIOLOGICAL ENGINEERING Co.,Ltd. Registration number: Y2022310000220 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20231023 Granted publication date: 20150513 Pledgee: Industrial Bank Co.,Ltd. Shanghai Putuo sub branch Pledgor: NANTONG LICHENG BIOLOGICAL ENGINEERING Co.,Ltd.|Nantong Licheng Biotechnology Co.,Ltd. Registration number: Y2022310000220 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Health foods that lower blood pressure and aid sleep Effective date of registration: 20231101 Granted publication date: 20150513 Pledgee: Industrial Bank Co.,Ltd. Shanghai Putuo sub branch Pledgor: NANTONG LICHENG BIOLOGICAL ENGINEERING Co.,Ltd.|Nantong Licheng Biotechnology Co.,Ltd. Registration number: Y2023310000703 |